Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.67 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363001 | 1.00 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL29483946 | 1.00 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL358119 | 1.00 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL362251 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL14831148 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL24722227 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL14831515 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL8497748 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL22163010 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL361149 | 0.98 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002438-A1 | MELANOCORTIN LIGANDS AND METHODS OF USE THEREOF | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2024-01-04 | — | — | US | claimed |
| EP-2709645-B1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS INC (US) | 2023-08-09 | — | — | EP | claimed |
| EP-4696699-A1 | ? OPIOID RECEPTOR AGONIST AND USE THEREOF | Chengdu Aoda Biotechnology Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | disclosed |
| CN-119031938-A | Compounds and uses | 同宜医药（苏州）有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024073622-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2022112865-A1 | MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ANBITION S.R.L. (IT) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112866-A1 | USE OF MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | ANBITION S.R.L. (IT) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022026633-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-11149066-B2 | Thrombospondin 1-binding peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20200131230-A1 | THROMBOSPONDIN 1-BINDING PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| WO-2015034920-A2 | GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR COMPOSITIONS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2010053548-A2 | PTHR1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-1100816-B1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-6489440-B1 | Cyclic compounds | BASILEA PHARMACEUTICA AG (CH) | 2002-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149066-B2 | Thrombospondin 1-binding peptide | SERPINC1, TEK, ARGLU1 | GSR 4846/4885RNPEP 364/4885GNAI3 2915/4885 |
| US-20200131230-A1 | THROMBOSPONDIN 1-BINDING PEPTIDE | SERPINC1, TEK, ARGLU1 | GSR 4846/4885RNPEP 364/4885GNAI3 2915/4885 |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL17A, IL36G | GSR 4052/4885RNPEP 323/4885GNAI3 2682/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | GSR 2517/4885RNPEP 2363/4885GNAI3 3357/4885 |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | GSR 2345/4885RNPEP 223/4885GNAI3 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.